SAGE's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2,564.74 -- higher than 98.56% of US-listed equities with positive expected earnings growth.
With a price/sales ratio of 354.98, Sage Therapeutics Inc has a higher such ratio than 98.62% of stocks in our set.
Revenue growth over the past 12 months for Sage Therapeutics Inc comes in at 452.76%, a number that bests 98.47% of the US stocks we're tracking.
If you're looking for stocks that are quantitatively similar to Sage Therapeutics Inc, a group of peers worth examining would be PRTA, RESN, HRTX, MXL, and WATT.
SAGE's SEC filings can be seen here. And to visit Sage Therapeutics Inc's official web site, go to www.sagerx.com.
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. The company was founded in 2010 and is based in Cambridge, Massachusetts.
Upgrades * According to Wedbush, the prior rating for Sage Therapeutics Inc (NASDAQ: SAGE) was changed from Neutral to Outperform. Sage Therapeutics earned $2.08 in the second quarter, compared to $3.28 in the year-ago quarter. The current stock performance of Sage Therapeutics shows a 52-week-high of $167.82 and a 52-week-low of $25.01. Moreover, at the end of the last trading period, the closing price was at $54.25. * According to Stifel, the prior rating for Photronics Inc (NASDAQ: PLAB) was changed from Hold to Buy. For the third quarter, Photronics had an EPS of $0.17, compared to year-ago quarter EPS of $0.10. At the moment, the stock has a 52-week-high of $16.75 and a 52-week-low of $8.31. Photronics closed at $8.73 at the end of the last trading period. * For ACM Research In...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, will host “FutureCast: An R&D Portfolio Review” to discuss the Company’s research and development strategy, and clinical progress in its key depression, neurology, and neuropsychiatry franchise programs. “The team at Sage continues to follow the scien
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020 at 2:45 p.m. ET. A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sage